|Bid||242.00 x 800|
|Ask||292.40 x 800|
|Day's range||261.01 - 267.25|
|52-week range||187.16 - 311.88|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||12.37|
|Earnings date||01 May 2023 - 05 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||321.07|
SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United StatesCAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). On the question, “Is the available evidenc
Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session.
Over time, Biogen (NASDAQ: BIIB) created a true success story. Competition for Biogen's MS blockbuster Tecfidera, and for other key products, entered the market. Now, though, Biogen may have found that new growth source.